Valneva's IXCHIQ® Shows Robust Antibody Durability After Three Years

Positive Antibody Persistence Data for IXCHIQ®

Saint-Herblain (France) – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a dedicated specialty vaccine company, has recently disclosed promising antibody persistence data that were observed three years post-vaccination with a single dose of its chikungunya vaccine, IXCHIQ®. These findings align with Valneva’s expectations, demonstrating robust and lasting antibody levels across various age demographics involved in the study.

Study Highlights and Key Findings

This vital study involved 278 healthy adults, of whom an encouraging 96% maintained neutralizing antibody titers significantly above the designated seroresponse threshold three years after vaccination. This promising result confirms the primary endpoint of the study. Furthermore, the persistence of these antibodies in older adults aged 65 and above showed similar levels to those in younger adults, indicating that age does not diminish the vaccine's effectiveness.

Ongoing Safety Monitoring

Study VLA1553-303 benefitted from financial support by the Coalition for Epidemic Preparedness Innovations (CEPI) and the EU’s Horizon Europe program. It has also prioritized long-term safety assessments by tracking any significant adverse events related to previous phases of the study. Notably, the latest analysis has displayed no safety concerns since all safety data was determined complete at the two-year follow-up mark.

Expert Insights on Vaccine Efficacy

Juan Carlos Jaramillo, M.D., Chief Medical Officer of Valneva, expressed his excitement about the three-year data, stating, “These findings accentuate IXCHIQ®'s exceptional profile and its ability to generate a robust, durable antibody response from a single vaccination. This is significant for both travelers and residents in endemic regions, especially in lower-income countries where vaccine accessibility is frequently a challenge.”

Approval and Market Launch

IXCHIQ® stands out as the first licensed chikungunya vaccine globally. Currently, the vaccine has received approvals in several regions, including the U.S., Europe, and Canada, for the prevention of chikungunya virus-related sickness among individuals aged 18 and older. Recently, Valneva submitted applications to extend its use to adolescents aged 12 to 17 years, alongside including persuasive two-year antibody persistence data.

Expanding Vaccine Accessibility and New Developments

The introduction of IXCHIQ® in the U.S. began in early March, following favorable recommendations by the CDC. In addition, launches are currently in progress in France and Canada. Valneva is not only aiming to enhance sales but is also working diligently to expand the accessibility of its vaccine.

Plans for Future Authorization

The company anticipates receiving marketing authorization in Brazil by the year-end and has bolstered its partnership with CEPI to improve access to IXCHIQ® in low- and middle-income countries, especially in areas affected by chikungunya outbreaks. CEPI is providing Valneva with a substantial funding boost of up to $41.3 million over the next five years.

Understanding Chikungunya

Chikungunya virus (CHIKV) is transmitted through the bites of infected Aedes mosquitoes, leading to debilitating symptoms such as fever, severe joint pain, headaches, nausea, fatigue, and rash. The lasting effects of joint pain can linger for weeks to years. Since its resurgence in 2004, chikungunya has triggered widespread outbreaks across 110+ countries in Asia, Africa, Europe, and the Americas, with over 3.7 million reported cases between 2013 and 2023 in the Americas alone.

About Valneva SE

Valneva SE is committed to developing, manufacturing, and commercializing vaccines that target various infectious diseases with significant unmet needs. The company utilizes a specialized approach that encompasses multiple vaccine modalities to provide first-rate vaccine solutions. With a proven track record, Valneva has advanced several vaccine candidates, including its pioneering chikungunya vaccine, from initial research to regulatory approval.

Frequently Asked Questions

What is IXCHIQ® and its significance?

IXCHIQ® is the world's first and only licensed chikungunya vaccine that provides long-lasting immunity with a single shot, making it vital for preventing this mosquito-borne illness.

How did the antibody levels perform three years after vaccination?

Three years post-vaccination, 96% of participants maintained neutralizing antibody levels well above the necessary seroresponse threshold, confirming the vaccine's durability.

What age groups were included in the vaccine study?

The study assessed the vaccine's effectiveness in both older adults (aged 65+) and younger adults (aged 18-64), with similar outcomes indicating durability across both demographics.

What are the future plans for IXCHIQ®?

Valneva intends to expand the vaccine’s usage to adolescents and increase its market presence in emerging markets, including Brazil.

How does chikungunya affect individuals?

Chikungunya can cause severe joint pain, fever, and other significant health issues that can severely impact daily life and may last for years after initial infection.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.